Literature DB >> 31270584

Does diabetes prevention translate into reduced long-term vascular complications of diabetes?

David M Nathan1, Peter H Bennett2, Jill P Crandall3, Sharon L Edelstein4, Ronald B Goldberg5, Steven E Kahn6, William C Knowler2, Kieren J Mather7, Sunder Mudaliar8, Trevor J Orchard9, Marinella Temprosa4, Neil H White10.   

Abstract

The global epidemic of type 2 diabetes has prompted numerous studies and public health efforts to reduce its development. A variety of interventions, including lifestyle modifications and pharmacological agents directed at ameliorating the major risk factors for type 2 diabetes, are of proven efficacy in reducing the development of type 2 diabetes in people with impaired glucose tolerance. While prevention of the hyperglycaemia characteristic of diabetes is arguably an important, clinically relevant outcome, a more compelling outcome with greater clinical significance is the prevention or reduction of the relatively diabetes-specific microvascular and less-specific cardiovascular disease (CVD) complications associated with diabetes. These complications cause the majority of morbidity and excess mortality associated with diabetes. Any reduction in diabetes should, logically, also reduce the occurrence of its long-term complications; however, most diabetes prevention trials have not been of sufficient duration to allow such an evaluation. The limited long-term data, largely from the Da Qing Diabetes Prevention Study (DQDPS) and the Diabetes Prevention Program (DPP) and their respective follow-up studies (DQDPOS and DPPOS), suggest a reduction in microvascular complications and amelioration of CVD risk factors. Only the DQDPOS and Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) studies have shown a reduction in CVD events and only DQDPOS has demonstrated a decrease in CVD and overall mortality. While these limited data are promising, whether diabetes prevention directly reduces complication-related morbidity and mortality remains unclear. Longer follow-up of prevention studies is needed to supplement the limited current clinical trial data, to help differentiate the effects of diabetes prevention itself from the means used to reduce diabetes development and to understand the balance among benefits, risks and costs of prevention.

Entities:  

Keywords:  Cardiovascular disease; Cardiovascular disease risk factors; Diabetes prevention; Long-term diabetes complications; Microvascular disease; Review

Mesh:

Substances:

Year:  2019        PMID: 31270584      PMCID: PMC6818092          DOI: 10.1007/s00125-019-4928-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  43 in total

1.  Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study.

Authors:  T J Orchard; M Temprosa; E Barrett-Connor; S E Fowler; R B Goldberg; K J Mather; S M Marcovina; M Montez; R E Ratner; C D Saudek; H Sherif; K E Watson
Journal:  Diabet Med       Date:  2013-01       Impact factor: 4.359

2.  Diabetic retinopathy assessed by fundus photography in Pima Indians with impaired glucose tolerance and NIDDM.

Authors:  D K Nagi; D J Pettitt; P H Bennett; R Klein; W C Knowler
Journal:  Diabet Med       Date:  1997-06       Impact factor: 4.359

3.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

Authors:  H C Gerstein; S Yusuf; J Bosch; J Pogue; P Sheridan; N Dinccag; M Hanefeld; B Hoogwerf; M Laakso; V Mohan; J Shaw; B Zinman; R R Holman
Journal:  Lancet       Date:  2006-09-23       Impact factor: 79.321

4.  Basal insulin and cardiovascular and other outcomes in dysglycemia.

Authors:  Hertzel C Gerstein; Jackie Bosch; Gilles R Dagenais; Rafael Díaz; Hyejung Jung; Aldo P Maggioni; Janice Pogue; Jeffrey Probstfield; Ambady Ramachandran; Matthew C Riddle; Lars E Rydén; Salim Yusuf
Journal:  N Engl J Med       Date:  2012-06-11       Impact factor: 91.245

5.  Coronary heart disease and diabetic retinopathy in newly diagnosed diabetes in Da Qing, China: the Da Qing IGT and Diabetes Study.

Authors:  Y H Hu; X R Pan; P A Liu; G W Li; B V Howard; P H Bennett
Journal:  Acta Diabetol       Date:  1991       Impact factor: 4.280

6.  Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited.

Authors:  John M Lachin; Saul Genuth; David M Nathan; Bernard Zinman; Brandy N Rutledge
Journal:  Diabetes       Date:  2008-01-25       Impact factor: 9.461

7.  Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.

Authors:  Aramesh Saremi; Dawn C Schwenke; Thomas A Buchanan; Howard N Hodis; Wendy J Mack; Maryann Banerji; George A Bray; Stephen C Clement; Robert R Henry; Abbas E Kitabchi; Sunder Mudaliar; Robert E Ratner; Frankie B Stentz; Nicolas Musi; Devjit Tripathy; Ralph A DeFronzo; Peter D Reaven
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-21       Impact factor: 8.311

8.  Risk Factors for Cardiovascular Disease in Type 1 Diabetes.

Authors: 
Journal:  Diabetes       Date:  2016-02-19       Impact factor: 9.461

9.  Changes in Mortality in People With IGT Before and After the Onset of Diabetes During the 23-Year Follow-up of the Da Qing Diabetes Prevention Study.

Authors:  Qiuhong Gong; Ping Zhang; Jinping Wang; Yali An; Edward W Gregg; Hui Li; Bo Zhang; Ying Shuai; Wenying Yang; Yanyan Chen; Shuqian Liu; Michael M Engelgau; Yinghua Hu; Peter H Bennett; Guangwei Li
Journal:  Diabetes Care       Date:  2016-07-13       Impact factor: 19.112

10.  Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group.

Authors:  Ronald B Goldberg; Marinella Temprosa; Steven Haffner; Trevor J Orchard; Robert E Ratner; Sarah E Fowler; Kieren Mather; Santica Marcovina; Chris Saudek; Margaret J Matulik; David Price
Journal:  Diabetes Care       Date:  2009-01-26       Impact factor: 17.152

View more
  11 in total

1.  Good news from the Da Qing Diabetes Prevention Outcome Study-healthy lifestyles result in long-term cardiovascular benefits.

Authors:  Matti Uusitupa
Journal:  Ann Transl Med       Date:  2019-12

Review 2.  Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes.

Authors:  William C Knowler; Jill P Crandall
Journal:  Curr Diab Rep       Date:  2019-12-02       Impact factor: 4.810

3.  Associations of progression to diabetes and regression to normal glucose tolerance with development of cardiovascular and microvascular disease among people with impaired glucose tolerance: a secondary analysis of the 30 year Da Qing Diabetes Prevention Outcome Study.

Authors:  Yanyan Chen; Ping Zhang; Jinping Wang; Qiuhong Gong; Yali An; Xin Qian; Bo Zhang; Hui Li; Edward W Gregg; Peter H Bennett; Guangwei Li
Journal:  Diabetologia       Date:  2021-02-19       Impact factor: 10.122

4.  Network Pharmacology-Based Identification of the Mechanisms of Shen-Qi Compound Formula in Treating Diabetes Mellitus.

Authors:  Zhipeng Hu; Maoyi Yang; Liangjun Yang; Chunguang Xie; Hong Gao; Xiaoxu Fu; Hongyan Xie; Ya Liu
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-04       Impact factor: 2.629

5.  Prevention of Type 2 Diabetes by Lifestyle Changes: A Systematic Review and Meta-Analysis.

Authors:  Matti Uusitupa; Tauseef A Khan; Effie Viguiliouk; Hana Kahleova; Angela A Rivellese; Kjeld Hermansen; Andreas Pfeiffer; Anastasia Thanopoulou; Jordi Salas-Salvadó; Ursula Schwab; John L Sievenpiper
Journal:  Nutrients       Date:  2019-11-01       Impact factor: 5.717

6.  A comparison of sotagliflozin therapy for diabetes mellitus between week 24 with week 52 : A protocol for mixed treatment comparisons meta-analysis.

Authors:  Nie Zhang; Zhi-Qun Gu; Yun-Long Ding; Liu Yang; Mao-Bing Chen; Qi-Han Zheng
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

7.  Knowledge, attitude, and practice of patients with type 2 diabetes mellitus with regard to their disease: a cross-sectional study among Palestinians of the West Bank.

Authors:  Ramzi Shawahna; Saed Samaro; Zaid Ahmad
Journal:  BMC Public Health       Date:  2021-03-09       Impact factor: 3.295

8.  Use of Network Pharmacology to Explore the Mechanism of Gegen (Puerariae lobatae Radix) in the Treatment of Type 2 Diabetes Mellitus Associated with Hyperlipidemia.

Authors:  Guozhen Yuan; Shuai Shi; Qiulei Jia; Jingjing Shi; Shuqing Shi; Xuesong Zhang; Xintian Shou; Xueping Zhu; Yuanhui Hu
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-16       Impact factor: 2.629

9.  Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies.

Authors:  Sabrina Schlesinger; Manuela Neuenschwander; Janett Barbaresko; Alexander Lang; Haifa Maalmi; Wolfgang Rathmann; Michael Roden; Christian Herder
Journal:  Diabetologia       Date:  2021-10-31       Impact factor: 10.122

10.  Efficacy of lifestyle intervention in adults with impaired glucose tolerance with and without impaired fasting plasma glucose: A post hoc analysis of Da Qing Diabetes Prevention Outcome Study.

Authors:  Qiuhong Gong; Ping Zhang; Jinping Wang; Edward W Gregg; Yiling J Cheng; Guangwei Li; Peter H Bennett
Journal:  Diabetes Obes Metab       Date:  2021-07-27       Impact factor: 6.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.